fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Artemisinin as cancer therapy- Myeloma, Liver, and Melanoma

Share Button

“Artemisinin (ART) is a chemical compound extracted from the wormwood plant, Artemisia annua L. It has been shown to selectively kill cancer cells in vitro and retard the growth of implanted fibrosarcoma tumors in rats.

There are a number of cancer therapies that have shown real cancer killing properties yet are not researched enough to instill confidence in the average cancer patient. Artemisinin is one of these therapies. Sourcing and dosing are two of the most important aspects of a therapy that is not thoroughly researched.

I often ask myself what I would do if my cancer, multiple myeloma, returns. Also, I ask myself what I would do if I developed a treatment-related, secondary cancer. Conventional chemotherapy didn’t work the first time around so why would it work this time?

Artemisinin would be on my top five list of future cancer therapies- It’s not rocket science. The phrase from one of the studies linked below, “inexpensive and effective cancer agents” fits my basic cancer therapy criteria.

In fact, there are a host of integrative and alternative research-based cancer therapies out there. For information about therapies that may kill your cancer without killing you, scroll down the page, post a question or a comment and I will reply ASAP.

Thank you,

David Emerson

  • Multiple Myeloma Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


A Novel Putative Mechanism of Anti-Myeloma Activity Targeted Against Heat Shock Protein 27 by Derivative of Artemisinin, Artesunate.

“Recent introduction of molecular targeted drugs such as bortezomib and IMIDs in the clinical settings has achieved the improved treatment outcome of multiple myeloma (MM). However, MM is still an incurable disease and these drugs also possess serious adverse reactions, therefore, safe and more effective therapy should be established. Artesunate (ART) is a semi-synthetic derivative of artemisinin and is widely used for the treatment of malaria as a salvage therapy. Recent in vitro studies showed that ART also has an anti-tumor activity against several cancer cell lines. We thus investigated whether ART could possess anti-myeloma activity and demonstrated that apoptosis of myeloma cells is strongly induced by ART…”

Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds.

Once an artemisinin-tagged transferrin molecule is endocytosed, iron is released and reacts with artemisinin moieties tagged to transferrin. Formation of free radicals kills the cancer cell. The authors have found that artemisinin-tagged transferrin is highly selective and potent in killing cancer cells. Thus, artemisinin and artemisinin-tagged iron-carrying compounds could be developed into powerful anticancer drugs..”

Artemisinin Cancer treatment

ART is undergoing early research and testing for the treatment of cancer.[24][25] Chinese scientists have shown ART has significant anticancer effects against human hepatoma cells.[26] ART has a peroxide lactone group in its structure, and it is thought that when the peroxide comes into contact with high iron concentrations (common in cancerous cells), the molecule becomes unstable and releases reactive oxygen species. It has been shown to reduce angiogenesis and the expression of vascular endothelial growth factor in some tissue cultures. Recent pharmacological evidence demonstrates the artemisinin-derivative dihydroartemisinin targets human metastatic melanoma cells with induction of NOXA (phorbol-12-myristate-13-acetate-induced protein 1)-dependent mitochondrial apoptosis that occurs downstream of iron-dependent generation of cytotoxic oxidative stress.[27]“”

Artemisinin induces apoptosis in human cancer cells.

“ART is a chemical compound extracted from the wormwood plant, Artemisia annua L. It has been shown to selectively kill cancer cells in vitro and retard the growth of implanted fibrosarcoma tumors in rats. In the present research, we investigated its mechanism of cytotoxicity to cancer cells…

CONCLUSION:This rapid induction of apoptosis in cancer cells after treatment with DHA indicates that ART  and its analogs may be inexpensive and effective cancer agents.”

Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production.

In recent years, anticancer activity of ART has been reported both in vitro and in vivo. ART has inhibitory effects on cancer cell growth and anti-angiogenetic activity…We demonstrate that ART induces cell growth arrest in A375M, and affects A375P cells viability with cytotoxic and growth inhibitory effects, while it was not effective in contrasting proliferation of other tumor cell lines (MCF7 and MKN). In addition, ART affected the migratory ability of A375M cells by reducing metalloproteinase 2 (MMP-2) production and down-regulating alpha v beta 3 integrin expression. These findings introduce a potential of ART as a chemotherapeutic agent in melanoma treatment.”

Artemisinin: A Cancer Smart Bomb

“ART and its derivatives offer the possibility of using a non-toxic form of chemotherapy that is inexpensive and readily available. Because of its excellent safety profile, it should be a consideration for cancer treatment when conventional treatments have failed or when people refuse conventional therapies. For more information check out our video on NaturalNews.tv at http://naturalnews.tv/v.asp?v=5E89C18C669ACC…”

Multiple Myeloma Chemotherapy- Artesunate Beats MDR

“Artesunate’s (ART) unique mechanism probably was at least partially responsible for, its ability to act synergistically with multiple anti-myeloma agents…”

Conventional oncology cannot cure multiple myeloma. Repeated multiple myeloma chemotherapy regimens will result in remission, relapse, remission, relapse and multi-drug resistance I don’t want to sound negative but a multiple myeloma diagnosis is a death sentence eventually. The greatest challenge of the multiple myeloma (MM) patient then,  is multi-drug resistence (MDR).

The good news is that conventional oncology has gotten pretty good at putting the newly diagnosed MM patient into remission. The challenge then, is for the patient to

  1. remain in remission or to
  2. achieve remission a second, third, fourth, etc. time.

If MM patients could reach remission repeatedly for the rest of their lives, then this incurable blood cancer really could become a chronic disease. Unfotunately, most MM patients eventually face MDR. Their MM no longer responds to therapy. Any therapy.

 

According to the studies linked and excerpted below, ART may be able to overcome MDR. Or to put it in the jargon of the study below “ART inhibits viability of MM cell lines and primary MM cells, regardless of prior drug resistance...” The critical phrase is “regardless of prior drug resistance.”

The drawback to the studies below is that they are in vitro aka in a test tube, and not in actual MM patients. Another potential drawback is that ART is not the standard-of-care for MM and therefore will not be know by your oncologist.


Artesunate/Artemisinin

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis

“Artesunate’s (ART) unique mechanism probably was at least partially responsible for, its ability to act synergistically with multiple anti-myeloma agents…

Nevertheless, treatment of patients diagnosed with high-risk MM [] or those who relapse after exposure to a multitude of anti-MM agents remains a significant challenge…

RESULTS- ART inhibits viability of MM cell lines and primary MM cells, regardless of prior drug resistance, in a dose- and time-dependent manner…

DISCUSSION-Artemisinin and its derivative ART have been reported to have anticancer activity in many different in vitro tumor models []. This report establishes ART’s in vitro effectiveness against MM cells and elucidates the mechanisms by which this agent induces apoptosis of MM cells

Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.

“Nevertheless, over time many patients relapse and develop resistance to treatment, and efforts are needed to overcome drug resistance. The widely used malaria drug artesunate has been reported to have antitumor activity, and we aimed to test the effects of artesunate on a panel of myeloma and lymphoma cells…

RESULTS: ART treatment efficiently inhibited cell growth and induced apoptosis in cell lines…Furthermore, some primary myeloma cells were also sensitive to ART at doses around 10 μm. Concentrations of this order are pharmacologically relevant as they can be obtained in plasma after intravenous administration of ART for malaria treatment.

CONCLUSION: Our findings indicate that ART is a potential drug for treatment of multiple myeloma and DLBCL at doses of the same order as currently in use for treatment of malaria without serious adverse effects.”

Leave a Comment:

29 comments
Add Your Reply